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Acute rejection before cytomegalovirus infection enhances von chronic infection of ECs may underlie intragraft as well
Willebrand factor and soluble VCAM-1 in blood. as systemic vascular pathology in the long run. Hence,
Background. Human cytomegalovirus (HCMV) infections the possible role of HCMV infection in chronic trans-in transplantation patients are associated with vascular endo-
plant dysfunction or accelerated arteriosclerosis has at-thelial damage. This is reflected by the appearance of cytome-
tracted recent interest [2, 3].galic endothelial cells (CECs) and noninfected endothelial cells
(ECs) in blood. To get more insight in the extent of vascular Acute infection of ECs is directly evidenced by the
damage during HCMV infection, we investigated the levels of appearance of cytomegalic ECs (CECs) in peripheral
soluble markers during HCMV infection in relationship to EC blood of patients with active HCMV infection [4–6]. Thelevels and also preceding the acute rejection episodes.
occurrence of CECs was related to the severity of infec-Methods. Of 46 kidney transplant patients, plasma levels of
tion and organ involvement [5], although the two othervon Willebrand factor (VWF), soluble intercellular adhesion
molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 studies could not confirm this finding [4, 6]. In a previous
(sVCAM-1), and soluble E-selectin (sE-sel) were analyzed dur- study of kidney transplant recipients with HCMV infec-
ing the course of HCMV infection.
tion, we found that CECs only occurred in patients withResults. Plasma levels of VWF and sVCAM-1 increased two-
moderate to high HCMV antigenemia and correlatedfold during severe HCMV infection. Moreover, the plasma
levels of VWF correlated with detectable cytomegalic and non- with HCMV-associated clinical symptoms [7]. Further-
infected ECs in blood. The kinetics of changes in VWF and ECs more, noninfected ECs also were observed in these pa-
(CEC and EC) demonstrated the relationship with HCMV- tients during HCMV infection. This indicates that not
induced vascular damage. Levels of sICAM-1 and sE-sel in
only infection itself caused endothelial damage, but alsoplasma did not significantly change during HCMV infection.
a more generalized form of endothelial damage was in-Interestingly, the combination of HCMV infection and preced-
ing acute transplant rejection caused the highest increases of duced. To date, no data are available about whether the
VWF and sVCAM-1 plasma levels, reflecting an enhanced sus- occurrence of CEC and/or EC in blood is reflected in
ceptibility for endothelial damage at the moment of infection. plasma parameters of endothelial activation or endothe-Conclusion. CMV infection is associated with vascular dam-
lial damage.age, and the vascular damage during CMV infection is enhanced
Apart from cytomegalovirus infections, many factorsif patients experienced acute rejection before CMV infection.
may cause endothelial damage to both the allograft and
the recipient, such as reperfusion injury, acute rejection
episodes, or thrombotic complications. As a result ofHuman cytomegalovirus (HCMV) infections are an
chronic transplant dysfunction, the allograft may be lost.important cause of morbidity in the post-transplant pe-
riod [1] and may result in a CMV-associated syndrome. Damage as well as inflammatory stimuli induce the
Infected vascular endothelial cells (ECs) may contribute release of von Willebrand factor (VWF) by ECs, and the
to HCMV-related organ dysfunction and dissemination serum level of VWF is considered to be one of the best
of the virus. Aside from acute effects of HCMV infection, available markers for endothelial damage [8–12]. Inter-
cellular adhesion molecule-1 (ICAM-1), an adhesion mol-
ecule expressed on many cell types, is up-regulated uponKey words: soluble ICAM, vascular cell adhesion molecule, endothelial
cells, E-selectin, transplantation, kidney rejection. endothelial activation by cytokines such as interleukin-1
(IL-1) and tumor necrosis factor-a (TNF-a). This acti-Received for publication December 23, 1999
vation also leads to increased shedding of the solubleand in revised form May 2, 2000
Accepted for publication June 15, 2000 form, sICAM-1 [13]. Vascular cell adhesion molecule-1
(VCAM-1) is induced after activation by cytokines. It isÓ 2000 by the International Society of Nephrology
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thought to be more endothelium specific than sICAM-1, followed by five courses 4 mg/kg of ATG given on alter-
native days (Merieux, Lyon, France) in case of steroid-although dendritic cells, macrophages, vascular smooth
muscle cells and epithelia express VCAM-1 as well. Fi- resistant rejection. Vascular rejection was treated with
ATG and plasmapheresis. Thirty patients, who had IgGnally, E-selectin (E-sel) is exclusively found on activated
endothelium. Both increased sICAM-1 and sVCAM-1 antibodies against HCMV late antigen before trans-
plantation, were considered seropositive for HCMV [19].are associated with allograft rejection and HCMV dis-
ease [14, 15]. Levels of soluble E-sel (sE-sel) did not The HCMV antigenemia was routinely assessed twice a
week starting at day 15 after transplantation. No HCMV-correlate with acute rejection episodes [16, 17] nor with
CMV infection [17]. However, the data concerning CMV prophylaxis like ganciclovir, acyclovir, or hyperimmune
globulin was given. Ten patients who developed a moder-infection are based on a few number of patients. Consid-
ering the specificity of E-sel for activated endothelium, ate to severe HCMV infection received ganciclovir at
early clinical symptoms and/or rising HCMV antigene-we included measurement of sE-sel in our study.
In this prospective study, vascular damage during mia values.
Plasma samples were collected at day 15 after trans-CMV infection was investigated. We hypothesized that
the appearance of CECs and ECs in patients with symp- plantation and weekly after the onset of HCMV antigen-
emia until it became negative (N 5 29) or less than 5tomatic HCMV infection would be related to increased
levels of plasma parameters VWF, sICAM-1, sVCAM- pp65 positive polymorphonuclear cells (PMNs)/50,000
cells (N 5 7), approximately 60 to 100 days after trans-1, and sE-sel. For this, we analyzed and correlated the
increases in plasma levels of the soluble parameters with plantation. Plasma samples of patients without HCMV
infection were sampled at days 15, 40, 50, and 60.HCMV viral load, CEC, EC, and clinical symptoms.
Acute rejection not only results in increased plasma lev-
HCMV antigenemiaels of VWF, sVCAM-1, and sICAM-1 [12, 14, 15], but
during HCMV infection, it causes a higher incidence of The HCMV antigenemia test was performed ac-
cording to the procedure recently reviewed for standard-ECs in blood and thus endothelial damage [7]. Hence,
we also studied the relationship of changes in plasma ization [1]. Briefly, peripheral blood leukocytes were de-
xtran sedimented followed by lysis of erythrocytes withlevels during HCMV infection and preceding acute rejec-
tion episodes that occurred before HCMV infection. NH4Cl. After two washes, the leukocytes were counted,
and cytospots were prepared. Cytospots were fixed with
paraformaldehyde, followed by a permeabilization step
METHODS
with NP40. Indirect peroxidase staining was with C10/
Patients C11, a mixture of two mouse monoclonal antibodies
directed to HCMV pp65 [20]. Pp65-positive cells perSixty-five consecutive patients were eligible for our
prospective study after renal transplantation [35 males spot were counted, while the number of negative cells
per spot was determined by automated image analysis.and 30 females, median age 48 years (range 18 to 70
years)]. Exclusion criteria were HCMV antigenemia at The HCMV antigenemia score was calculated from the
number of positive cells per 50,000 leukocytes. Two spotsthe start of the prospective study (15 days post-trans-
plantation, N 5 4) or a short period of HCMV antigene- were analyzed for each patient sample. In earlier work,
we showed that the antigenemia score correlated withmia (no samples obtained, N 5 12), endothelial damage
caused by thrombotic thrombocytopenic purpura or he- viral load [21]. Patients were divided into four groups
based on the maximum obtained HCMV antigenemiamolytic uremic syndrome (N 5 1), and requirement of
percutaneous transluminal coronary angioplasty (N 5 2). values by the individual patients. These were groups 1
to 4: no, low (1 to 10 pp651 PMN/50,000 cells), moderateForty-three patients received a cadaveric transplant;
three patients received a kidney from a living related (11 to 100), and high (.100), respectively.
donor. Initial immunosuppression consisted of cyclo-
von Willebrand factorsporine A (Novartis, Basle, Switzerland) and low-dose
prednisolone; 20 patients additionally received myco- von Willebrand factor levels were measured in citra-
ted plasma by an enzyme-linked immunosorbent assayphenolate mofetil (Roche, Basle, Switzerland). Seven
patients received an induction course of OKT3 (Jan- (ELISA) using commercially available antibodies (Da-
kopatts, Glostrup, Denmark). In short, microtiter platessen Gilag, Belgium) or antithymocyte immunoglobulin
(ATG; Fresenius, Oberursel, Germany), either because (Immunoplate Maxisorb; Nunc, Roskilde, Denmark) were
coated with polyclonal rabbit-anti-human VWF. Theof high anti-human lymphocyte antigen antibodies or
retransplantation. Rejection was diagnosed according to plates were incubated with plasma samples diluted 1:50
and 1:200 or standard control plasma (dilution rangeBanff criteria [18]. Interstitial rejection was treated with
1 g methylprednisolone intravenously on three consecu- 1.25% to 500% of a 1:100 prediluted plasma), followed
by a horseradish peroxidase (HRP)-conjugated poly-tive days (Solu-Medrol; Upjohn, Kalamazoo, MI, USA),
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clonal rabbit anti-human VWF antibody. The last step cells (MNCs) were isolated by density centrifugation us-
was a colorimetric reaction with ortho-phenylene-dia- ing Lymfoprep (Nycomed Pharma AS, Oslo, Norway).
mine (OPD), after which OD could be measured. Results One 3 105 MNCs were cytocentrifuged on a slide. The
are expressed as percentages of a standard composed of cytospots were stained by indirect immunofluorescence
pooled human plasma. with the following antibodies: C10/C11 directed against
HCMV pp65 and E1/1 2.3 directed to a 90 kD cell surface
Soluble ICAM-1 ELISA antigen of ECs [22]. Four cytospots were analyzed if the
Soluble ICAM-1 in ethylenediaminetetraacetic acid concentration of MNC/mL blood was 1.5 3 106 or less;
(EDTA) plasma was measured using a commercially otherwise, six to eight cytospots were analyzed. The num-
available sICAM-1 module kit (Bender MedSystems, ber of analyzed slides represented a detection limit of
Vienna, Austria). In brief, ELISA plates (Nunc Immu- 20 CEC or EC/mL blood in 95% of all samples.
noplate Maxisorb) were incubated with a monoclonal
antibody directed against ICAM-1. Unbound sites were Statistics
blocked with 0.5% bovine serum albumin (BSA), 0.05% The distribution of patients among the different
Tween. Plasma samples at a dilution of 1:100 or serial
groups was tested using contingency tables (x2 test). Dif-
twofold dilution of sICAM-1 standard protein (ranging
ferences between two groups were analyzed using thefrom 0.63 to 10.0 ng/mL) were applied. HRP-conjugated
Mann–Whitney test. Multiple groups were analyzed us-anti–ICAM-1 monoclonal antibody was used as detec-
ing nonparametric analysis of variance (ANOVA);tion antibody and tetramethyl benzidine (TMB) as a
Kruskal-Wallis test. Dunn’s Multiple Comparison testsubstrate for the enzyme reaction. Accordingly, the stan-
was used as post-test if P , 0.05. Multiple regressiondard the sICAM-1 concentrations in the samples could
analysis was performed using Systat software. Clinicalbe calculated. If the sample OD exceeded the OD of
symptoms, the occurrence of CEC, EC, and acute rejec-the standard, the sample concentration was adjusted to
tion episodes were analyzed as categorical variables, and1000 ng/mL. Five samples obtained during HCMV infec-
the severity of HCMV infection was analyzed as a contin-tion of five patients were set at 1000 ng/mL.
uous variable.
Soluble VCAM-1 ELISA
Levels of sVCAM-1 were determined in EDTA plasma
RESULTSby ELISA using a commercially available sVCAM-1 mod-
Patientsule kit (Bender MedSystems). The protocol for this mod-
ule kit was similar to the protocol used to measure Forty-six kidney transplant patients were included (to-
sICAM-1, except for the dilutions of both the standard tal number of samples 274) and classified into groups 1
protein and the plasma samples. Dilutions of the to 4, with no (N 5 10), low (N 5 12), moderate (N 5
sVCAM-1 standard protein were made to a range of 3.2 11), or high HCMV viral load (N 5 13), respectively
to 100 ng/mL, and plasma samples were applied at a (Table 1). Signs and symptoms of HCMV infection were
dilution of 1:50. The maximum detectable value in our only observed in patients with moderate or high viral
system was 5000 ng/mL. Plasma samples exceeding the load: 5 out of 11 of group 3 and 10 out of 13 of group
maximal OD of the standard were set at 5000 ng/mL 4 (P , 0.001). They had at least one sign or symptom
(N 5 4, all during HCMV infection). of otherwise unexplained fever, malaise, leukocytopenia,
thrombocytopenia, and elevated serum levels of liverSoluble E-selectin ELISA
enzymes. Of all patients, 24 patients experienced one
Soluble E-sel in EDTA plasma was studied using a
or more rejection episodes before the study period of
commercially available ELISA kit (Bender MedSys-
HCMV infection. The median time span from diagnosistems). Microtiter wells precoated with a monoclonal an-
of rejection to the onset of HCMV infection was 16.5tibody against human sE-sel were incubated with an
days (range 7 to 73 days). The patients with acute rejec-E-sel standard (range 0.8 to 50 ng/mL) or fivefold diluted
tion that preceded HCMV infection or occurred beforeplasma samples. In the next step, without washing, an
the expected onset of HCMV infection (group 1) wereanti–sE-sel monoclonal antibody conjugated to HRP was
equally distributed among the four groups (P 5 0.45;added. After a color reaction with TMB, the optical
Table 1). Twelve had interstitial rejection that resolveddensity was measured and the sE-sel concentrations in
after treatment with methylprednisolone; eight patientsthe samples could be calculated.
had steroid-resistant interstitial rejection, and the re-
Detection of CEC and EC maining four patients had vascular rejection. Patients
with vascular rejection were all in the moderate and highCytomegalic endothelial cells and ECs in blood were
analyzed as described recently [7]. In brief, mononuclear viral load groups.
Kas-Deelen et al: Rejection enhances CMV-induced VWF release2536
Table 1. Clinical and virological parameters of human cytomegalovirus (HCMV) patients after transplantation
HCMV
Acute rejection
Interstitial
HCMV-pp65 HCMV signs Steroid Steroid
antigenemiaa N Group Primary Secondary and symptoms Vascular resistant non-resistant
0 10 1 0 0 0 0 1 3
1–10 12 2 0 12 0 0 1 5
11–100 11 3 3 9 5 2 5 1
.100 13 4 8 5 10 2 1 3
Total 46 11 26 15 4 8 12
a Number of positive granulocytes/50,000
von Willebrand factor Soluble VCAM-1
Baseline levels were obtained before HCMV infection At 15 days post-transplantation, values of sVCAM-1
at 15-days post-transplantation. In transplant recipients, were higher in patients (median 1859 ng/mL, range 991
the median VWF baseline levels were higher (median to 3914 ng/mL) than in healthy individuals (normal range
275%, range 85 to 555%) than the standard of healthy 675 to 1693 ng/mL). Between the four groups, the base-
controls (range 50 to 150%). No differences among the line values were not different (P 5 0.38). The sVCAM-1
antigenemia groups were observed (P 5 0.52). In the values remained at the same level at 50 days after trans-
transplant recipients without HCMV infection, the VWF plantation (group 1 median decrease 11 ng/mL, range 1459
plasma levels decreased during time. At 50 days after to 2425 ng/mL). During HCMV infection, sVCAM-1
transplantation, that is, the median time of maximum plasma levels were measured at similar time points as
VWF levels in HCMV patients (groups 2 through 4),
VWF plasma levels. During HCMV infection, patients
the patients without HCMV infection (group 1) had a
with high HCMV viral load had sVCAM-1 plasma levelsmedian decrease of 62.5% (range 266 to 224%; Fig. 1).
almost double that of patient without HCMV infectionA comparison of the kinetics in VWF levels and kinetics
(group 4, median increase 1532.2 ng/mL; range 21531of HCMV antigenemia showed that maximum VWF lev-
to 3349 ng/mL, P , 0.05; Fig. 1).els were obtained a few days after maximum HCMV
antigenemia (3 to 7 days; Fig. 2). The increase of VWF
Soluble E-selectinduring HCMV infection was determined by subtracting
In 10 patients of group 1 and 10 patients of group 4,baseline levels from the maximum VWF levels. Although
sE-sel levels were determined at 15- and 50-days post-the median values showed a rise with increasing viral
transplantation, respectively. In these groups, four pa-load, only in patients of group 4, VWF plasma levels
were significantly higher than in patients without HCMV tients were included who had acute rejection episodes
infection (P , 0.01, group 4, median increase 113%; before or during HCMV infection. At 15-days post-trans-
range 234 to 308%; Fig. 1A). plantation, sE-sel plasma levels (median 46 ng/mL, range
6 to 101 ng/mL) were not different from healthy controls
Soluble ICAM-1 (median 52.8 ng/mL, range 23.0 to 79.2 ng/mL). Further-
At 15-days post-transplantation, the mean level of more, no differences in changes at 50 days between pa-
sICAM-1 in our patients was 354 ng/mL (range 138 to tients with a high HCMV viral load and patients without
853 ng/mL), which was about twofold higher than in HCMV infection were detectable (P 5 0.32; Fig. 1).
healthy individuals (range 130 to 297 ng/mL). Baseline
values were not different between the four groups (P 5 CEC and EC in peripheral blood
0.71). In patients without HCMV infection, baseline lev-
In patients with HCMV infection and detectable CECels of sICAM-1 were elevated at 15-days post-trans-
in peripheral blood (N 5 9), only VWF plasma levelsplantation and remained elevated at 50 days (group 1,
were significantly higher than in HCMV patients withoutmedian increase 12 ng/mL, range 2136 to 323 ng/mL;
CEC (P , 0.05; Fig. 2A). The occurrence of EC in bloodFig. 1). The sICAM-1 plasma levels during HCMV infec-
of patients (N 5 14) was related to increased levels oftion were determined at the same time points as VWF
VWF as well (P , 0.001; Fig. 2D). The presence oflevels, and changes of sICAM-1 plasma levels were ex-
CEC and/or EC in peripheral blood of patients was notpressed in the same way as those of VWF. No significant
associated with significantly altered levels of sVCAM-1differences in changes between the four patient groups
were demonstrated (P 5 0.11; Fig. 1B). or sICAM-1 (CEC, Fig. 2 B, C; EC, Fig. 2 E, F).
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Fig. 1. Changes in plasma levels of von Wille-
brand factor (VWF), soluble intercellular cel-
lular adhesion molecule-1 (sICAM-1), soluble
vascular cell adhesion molecule-1 (sVCAM-1),
and soluble E-selectin (sE-sel) during human
cytomegalovirus (HCMV) infection. Patients
were divided into four categories with no (0),
low (1 to 10 pp651 PMN/50,000), moderate
(11 to 100), and high (.100) HCMV viral
load. *P , 0.05 (high vs. none); **P , 0.01
(high vs. none).
Kinetics of soluble parameters and endothelial cells fluctuated during the infection, no correlation with HCMV
antigenemia values was observed (Fig. 3).during HCMV infection
The time kinetics of soluble parameters for endothelial Signs and symptoms
damage were demonstrated in a typical patient with
There were no significant differences in changes ofHCMV infection. This patient had a primary HCMV
plasma levels of VWF, sICAM-1, or sVCAM-1 betweeninfection without clinical signs and symptoms, and was
patients with and those without HCMV-associated clini-
not treated with ganciclovir. No acute rejection episodes
cal signs or symptoms (Fig. 4). Seven of 10 patients
were diagnosed. The patient had a high HCMV antigene- treated with ganciclovir had clinical symptoms.
mia with a maximum of 2500 pp651 PMNs/50,000 at
day 40 after transplantation that rapidly reduced to 480 Acute rejection episodes
pp651 PMNs/50,000 at day 47 and 1 pp651 PMN/50,000 To study the effect of preceding acute rejection epi-
at day 54. The maximum level of VWF was obtained at sodes and HCMV infection, a different classification was
day 47 (414%), and sVCAM-1 levels were elevated from made with the following categories: no acute rejection
day 40 until day 54 (,5000 ng/mL). After day 54, both and no HCMV infection, acute rejection only, HCMV
levels started to decrease. The highest levels of CEC in infection only, and acute rejection episodes before HCMV
blood were observed at day 47 (10.2 CEC/mL). This was infection. A nonparametric ANOVA on these four cate-
in accordance with the maximum levels of VWF and gories revealed significant differences in changes of VWF
sVCAM-1 and was slightly delayed compared with the plasma levels (P , 0.01). Between the individual catego-
HCMV antigenemia (7 days). This patient had no ECs ries, patients with HCMV infections and preceding acute
rejection episodes had a significantly higher increase ofduring CMV infection. Although levels of sICAM-1
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Fig. 2. Changes in plasma levels of VWF (A
and D), sICAM-1 (B and E) and sVCAM-1
(C and F ) of patients without (s) or with (d)
cytomegalic endothelial cells (CECs; A–C)
and endothelial cells (ECs; D–F) in peripheral
blood. **P , 0.01; ***P , 0.001.
Fig. 3. von Willebrand factor (VWF), sVCAM-1,
sICAM-1 plasma levels in a patient with a
primary HCMV infection. The bars indicate
CECs per milliliter of blood. This patient had
no acute rejection episodes and no clinical
signs and symptoms and was not treated with
ganciclovir. Symbols are: (s) CMAG; (m)
VWF; (r) sVCAM-1; (3) sICAM-1; (j) CEC
in peripheral blood.
VWF plasma levels (median increase 87.5, range 2143 resistant interstitial rejection, or interstitial rejection re-
sponding to steroid treatment showed no differences into 308) than patients without acute rejection and no
HCMV infection or patients with HCMV infection only the increase of VWF (data not shown).
The nonparametric ANOVA on changes of sVCAM-1(Fig. 5A). Analysis between vascular rejection, steroid-
Kas-Deelen et al: Rejection enhances CMV-induced VWF release 2539
Fig. 4. Changes in plasma levels of VWF (A),
sICAM-1 (B), and sVCAM-1 (C ) of patients
without (s) or with (d) HCMV-associated
symptoms.
plasma levels showed that the four categories were dif- VWF and sVCAM-1 with the severity of the infection
ferent (P 5 0.0215), although differences between indi- may reflect both an inflammatory response as well as
vidual categories did not reach significance (Fig. 5B). No damage to the endothelial surface of blood vessels. Of
significant differences were observed for sICAM-1 levels both markers, sVCAM-1 merely reflects endothelial acti-
in plasma among the four categories (Fig. 5C). vation. It is released by shedding of the membrane-
bound form [12]. VCAM-1, via interaction with ligand
Correlation very late antigen-4 (VLA-4), has an important role in
The changes of sVCAM-1 and sICAM-1 levels at 50- leukocyte adhesion and infiltration in tissues [23, 24].
days post-transplantation were correlated (r 5 0.50, P , Biopsies have shown that both during acute rejection
0.001). VWF showed no correlation with one of these and CMV infection the expression of VCAM-1 on several
adhesion molecules (sVCAM-1, r 5 0.28, P 5 0.06, and types of ECs is increased, frequently at sites of infiltrated
sICAM-1, r 5 0.27, P 5 0.07). inflammatory cells [25–28]. VWF can be released after
endothelial damage and to a lesser extent after an in-
Multiple logistic regression
flammatory stimulus [8]. The strong relationship be-
Multiple regression analysis identified VWF and tween increased levels of VWF and CECs, that is, HCMV
sVCAM-1 as independent parameters of the severity of infected and detached ECs, or EC indicates that endo-
infection (P , 0.001). Only VWF was shown to be an thelial damage is associated with HCMV infection. Thus,
independent predictor for the occurrence of CECs (P , based on the findings of elevated VWF levels in blood,
0.01), ECs (P , 0.01), and acute rejection episodes (P , we postulate that during HCMV infection, systemic low
0.05). VWF, sVCAM-1, or sICAM-1 were not predictive level vascular damage occurs.
for clinical symptoms of HCMV infection. Clinical signs and symptoms did not correlate with
levels of soluble adhesion molecules and VWF. A possi-
ble explanation could be that early diagnosis and rapidDISCUSSION
treatment of patients with ganciclovir mitigates the oc-In the present study, in patients with active HCMV
currence of clinical symptoms. However, in the presentinfections after renal transplantation, increased plasma
study, 70% of all patients treated with ganciclovir devel-levels of VWF were correlated to the occurrence of CECs
oped one or more clinical symptoms and had moderateand noninfected ECs in the blood stream. Increases in
to high HCMV antigenemia (Table 1). Therefore, in theVWF plasma levels as well as that of VCAM-1 were
present study, it is doubtful that treatment with gan-related to the severity of HCMV infection as measured
ciclovir has masked a possible correlation between symp-with the HCMV antigenemia test. The most pronounced
tomatology and levels of soluble markers.increases of both markers were observed in patients with
In two earlier small-scale studies, increased levels ofboth HCMV infection and preceding acute transplant
sICAM-1 or sVCAM-1 were reported during HCMVrejection episodes. Changes in plasma levels of sICAM-1
disease [14, 15]. Unfortunately, no information was givenor sE-sel did not relate to the severity of infection or
about the viral load or HCMV antigenemia in theseHCMV clinical symptoms.
studies. The present study, performed in a larger groupWith this study, we focused on the short-term effects
of HCMV patients with an infection ranging from mildof cytomegalovirus infection with a follow-up of 125 days
after transplantation. Interestingly, the correlation of to severe could not confirm the findings about sICAM-1
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tors, such as surgery and subsequent reperfusion of the
transplanted kidney [29], vascular injury caused by hyper-
tension or dialysis, or vascular damage by cyclosporine A
[9, 10]. In the absence of further complications like acute
rejection or HCMV infection the baseline of VWF de-
creased during time.
Recently, in a study of the occurrence of ECs in blood,
we observed increased endothelial damage during HCMV
infection, when this infection occurred after preceding
episodes of acute rejection [7]. In accordance with our
previous study, the present study demonstrated the in-
creased release of both VWF and sVCAM-1 during
HCMV infection in patients who experienced acute re-
jection before infection (Fig. 5). The question remains:
what is the possible nature of this relationship? We ob-
served no correlation between the time span from diag-
nosis of acute rejection to the onset of HCMV infection
(median time 16.5 days, range 7 to 73 days) and the
increase of VWF (r 5 0.027, P 5 0.91). Thus, patients
having CMV infection one week after acute rejection or
patients having CMV infection two months after acute
rejection showed similar increases in VWF levels during
HCMV infection. This argues against a continuous endo-
thelial damage during HCMV infection induced by acute
transplant rejection; otherwise, we would expect a de-
cline over time.
During acute transplant rejection but also during
chronic transplant rejection, we postulated that levels of
VWF are increased [11, 12]. Also, sVCAM-1 is reported
to be elevated during acute rejection, although other
studies could not find elevated levels of sVCAM-1 in
serum of patients with rejecting grafts [30–33]. The endo-
thelial damage induced by acute rejection is supposed to
originate from the transplanted graft. In contrast, CMV
induces a systemic infection that may involve many or-
gans. It seems likely to us that the occurrence of acute
rejection episodes, effectuated at the allograft, sensitizes
the endothelial surface, probably of the host, to HCMV-Fig. 5. Changes in plasma levels of VWF (A), sVCAM-1 (B), and
sICAM-1 (C ) of patients: without HCMV infection or acute rejection induced damage. Therefore, it would be interesting to
(none), with acute rejection but no HCMV infection (rej), with HCMV know the balance between levels of VWF and sVCAM-1infection but no acute rejection (HCMV), and with both HCMV infec-
released by ECs from the graft or from the host.tion and acute rejection (HCMV/rej). *P , 0.05 (HCMV/rej vs. none).
The enhancement of endothelial injury during HCMV
infection after acute rejection may have consequences in
the long run. Both acute rejection episodes and HCMV
and sVCAM-1. Thus, although most patients with clini- infection are identified as risk factors for chronic trans-
cal symptoms also had a high viral load, this did not result plant dysfunction [34–37]. With this study, we demonstrate
in a profile of increased inflammation and endothelial enhanced endothelial damage shortly after transplanta-
damage than patients without HCMV-associated clinical tion. No information is available about the underlying
signs and symptoms. mechanisms of the enhancement between acute trans-
At 15 days after transplantation, but before HCMV plant rejection and HCMV-associated vascular damage.
antigenemia became positive, the baseline of VWF in The elevated baseline levels of both VWF and soluble
our patient group was threefold higher than in healthy adhesion molecules indicate a low level of ongoing vascu-
individuals. Also, sICAM-1 and sVCAM-1 were elevated. lar activation and damage by multiple factors that might
Apparently, these patients had pre-existing endothelial predispose these patients to chronic graft dysfunction.
In vitro experiments have proven that CMV infectedactivation or damage that could be caused by many fac-
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human cytomegalovirus pathophysiology and management strate-ECs do not express VCAM-1 and MHC class II mole-
gies of patients after transplantation. Monogr Virol 21:262–279,cules, not even after cytokine induction such as TNF-a 1998
and interferon-g (IFN-g) [38]. Nevertheless CMV-infected 2. Hayry P, Lemstrom K, von Willebrand E, Tikkanen J, Koskinen
P: CMV infection and allograft rejection. Transplant Proc 30:916–cells evoke a powerful proliferative and cytolytic re-
917, 1998sponse in T cells from CMV seropositive donors. The 3. Bruggeman CA, van Dam JG: Role of cytomegalovirus infection
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